1 Min Read
Feb 20 (Reuters) - Fate Therapeutics Inc:
* FATE THERAPEUTICS ANNOUNCES FIRST SUBJECT TREATED WITH FATE-NK100 IN DIMENSION STUDY FOR ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.